Adynxx (ADYX) 10-Q 5 Nov 14 2014 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 31, 2014
Document Information [Line Items]	'	'
Entity Registrant Name	'Alliqua BioMedical, Inc.	'
Entity Central Index Key	'0001054274	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'ALQA	'
Entity Common Stock, Shares Outstanding	'	16,173,437
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2014	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current Assets:	'	'
Cash and cash equivalents	$19,887,588	$12,100,544
Accounts receivable	715,624	156,831
Inventory, net	1,099,142	501,469
Prepaid expenses and other current assets	313,590	88,390
Total current assets	22,015,944	12,847,234
Improvements and equipment, net	1,512,563	1,745,248
Intangible assets, net	4,619,963	2,258,477
Goodwill	4,100,295	425,969
Other assets	173,042	174,640
Total assets	32,421,807	17,451,568
Current Liabilities:	'	'
Accounts payable	1,101,745	746,609
Accrued expenses	1,788,999	1,267,899
Payable for distribution rights	33,333	333,333
Deferred revenue	39,000	39,000
Warrant liability	280,157	933,465
Deferred lease incentive liability - current	8,337	8,337
Other current liabilities	4,074	24,821
Total current liabilities	3,255,645	3,353,464
Contingent consideration	2,894,034	0
Deferred lease incentive liability, net of current	86,155	92,408
Deferred tax obligation	63,500	53,000
Total liabilities	6,299,334	3,498,872
Commitments and Contingencies	'	'
Stockholders' Equity	'	'
Preferred Stock, par value $0.001 per share, 1,000,000 shares authorized, no shares issued and outstanding	0	0
Common Stock, par value $0.001 per share, 45,714,286 shares authorized; 16,193,988 and 11,484,191 shares issued and outstanding as of September 30, 2014 and December 31, 2013, respectively	16,194	11,484
Additional paid-in capital	90,797,392	58,538,491
Accumulated deficit	-64,691,113	-44,597,279
Total stockholders' equity	26,122,473	13,952,696
Total liabilities and stockholders' equity	$32,421,807	$17,451,568

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)	Sep. 30, 2014	Dec. 31, 2013
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	45,714,286	45,714,286
Common stock, shares issued	16,193,988	11,484,191
Common stock, shares outstanding	16,193,988	11,484,191

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue, net of returns, allowances and discounts	$1,493,840	$437,985	$3,121,863	$1,328,911
Cost of revenues	915,811	574,219	2,384,225	1,507,069
Gross profit (loss)	578,029	-136,234	737,638	-178,158
Operating expenses	'	'	'	'
Selling, general and administrative, (inclusive of stock-based compensation compensation of $1,779,134 and $8,875,080 for the three month and nine month periods ended September 30, 2014 and $496,564 and $2,898,132 for the three and nine month periods ended September 30, 2013 - see Note 9)	5,480,380	2,095,926	20,083,015	6,532,154
Research and product development	0	33,602	0	63,204
Acquisition-related expenses	61,330	0	546,970	0
Change in fair value of contingent consideration liability	194,034	0	194,034	0
Total operating expenses	5,735,744	2,129,528	20,824,019	6,595,358
Loss from operations	-5,157,715	-2,265,762	-20,086,381	-6,773,516
Other income (expense)	'	'	'	'
Interest expense	0	-292	-384	-3,048
Interest income	8,779	31	22,755	75
Change in value of warrant liability	48,993	32,978	-19,324	-243,735
Total other income (expense)	57,772	32,717	3,047	-246,708
Loss before income tax provision	-5,099,943	-2,233,045	-20,083,334	-7,020,224
Income tax provision	3,500	3,000	10,500	9,000
Net loss	($5,103,443)	($2,236,045)	($20,093,834)	($7,029,224)
Basic and diluted net loss per common share (in dollars per share)	($0.33)	($0.31)	($1.41)	($1.09)
Weighted average shares used in computing basic and diluted net loss per common share (in shares)	15,666,697	7,105,147	14,269,239	6,452,353

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Parenthetical] (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Allocated Share-based Compensation Expense	$1,779,134	$496,564	$8,875,080	$2,898,132

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (USD $)		Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2013		$13,952,696	$11,484	$58,538,491	($44,597,279)
Balance (in shares) at Dec. 31, 2013		'	11,484,191	'	'
Issuance of common stock for the purchase of Choice Therapeutics, Inc.		1,992,854	274	1,992,580	0
Issuance of common stock for the purchase of Choice Therapeutics, Inc. (in shares)		'	273,368	'	'
Issuance of common stock for cash, net of issuance costs of $602,500		14,372,503	2,139	14,370,364	0
Issuance of common stock for cash, net of issuance costs of $602,500 (in shares)		'	2,139,287	'	'
Exercise of common stock options, net of tendered shares		1,243,867	277	1,243,590	0
Exercise of common stock options, net of tendered shares (in shares)		'	277,150	'	'
Exercise of warrants, net of issuance costs of $267,174		5,225,587	977	5,224,610	0
Exercise of warrants, net of issuance costs of $267,174 (in shares)		'	977,313	'	'
Cashless exercise of warrants		0	211	-211	0
Cashless exercise of warrants (in shares)		'	211,295	'	'
Extinguishment of warrant liability		672,632	0	672,632	0
Issuance of common stock for services		195,339	23	195,316	0
Issuance of common stock for services (in shares)		'	23,396	'	'
Stock-based compensation	[1]	9,130,114	837	9,129,277	0
Stock-based compensation (in shares)	[1]	'	836,491	'	'
Net settlement on vesting of restricted stock awards		-569,285	-77	-569,208	0
Net settlement on vesting of restricted stock awards (in shares)		'	-77,471	'	'
Warrant exchange		0	49	-49	0
Warrant exchange (in shares)		'	48,968	'	'
Net loss		-20,093,834	0	0	-20,093,834
Balance at Sep. 30, 2014		$26,122,473	$16,194	$90,797,392	($64,691,113)
Balance (in shares) at Sep. 30, 2014		'	16,193,988	'	'
[1]	Includes $307,189 that was part of accrued expenses as of December 31, 2013 and for the the year then ended, which was credited to equity upon the issuance of 34,086 restricted common shares during the nine months ended September 30, 2014.

CONDENSED_CONSOLIDATED_STATEME3

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY [Parenthetical] (USD $)	9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Accrued Liabilities	'	$307,189
Debt Conversion, Converted Instrument, Shares Issued	34,086	'
Common Stock [Member]	'	'
Payments of Stock Issuance Costs	602,500	'
Warrant [Member]	'	'
Payments of Stock Issuance Costs	$267,174	'

CONDENSED_CONSOLIDATED_STATEME4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash Flows From Operating Activities	'	'
Net loss	($20,093,834)	($7,029,224)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	769,128	443,393
Amortization of deferred lease incentive	-6,253	0
Deferred income taxes	10,500	9,000
Provision for inventory obsolescence	-65,493	-4,363
Stock-based compensation expense	8,822,925	2,270,690
Stock issued for services rendered	195,339	627,442
Change in value of warrant liability	19,324	243,735
Fair value adjustment to contingent consideration	194,034	0
Fair value of rent provided by related party	0	32,000
Changes in operating assets and liabilities:	'	'
Accounts receivable	-547,206	-35,673
Inventory	-135,219	17,990
Prepaid expenses and other current assets	-223,602	108,605
Accounts payable	281,642	-106,092
Accrued expenses and other current liabilities	599,209	291,004
Net Cash Used in Operating Activities	-10,179,506	-3,131,493
Cash Flows From Investing Activities	'	'
Payment for distribution rights	-300,000	0
Purchase of improvements and equipment	-6,596	0
Acquisition of business, net of $474 cash acquired	-1,999,526	0
Net Cash Used in Investing Activities	-2,306,122	0
Cash Flows From Financing Activities	'	'
Net proceeds from issuance of common stock	14,372,503	3,291,293
Proceeds from the exercise of stock options	1,243,867	0
Proceeds from the exercise of warrants	5,225,587	0
Payment of withholding taxes related to stock-based employee compensation	-569,285	0
Net Cash Provided by Financing Activities	20,272,672	3,291,293
Net Increase in Cash and Cash Equivalents	7,787,044	159,800
Cash and Cash Equivalents - Beginning of period	12,100,544	260,357
Cash and Cash Equivalents - End of period	19,887,588	420,157
Supplemental Disclosure of Cash Flows Information	'	'
Cash paid during the period for interest	384	3,048
Non-cash investing and financing activities:	'	'
Cashless warrant exercise	672,632	0
2013 Bonus awarded in equity	307,189	0
Warrant exchange	49	0
Acquisition of business:	'	'
Current assets, excluding cash and cash equivalents	408,548	0
Intangibles	2,683,000	0
Goodwill	3,674,326	0
Liabilities assumed	-73,494	0
Contingent consideration	-2,700,000	0
Issuance of common stock for acquisition	($1,992,854)	$0

CONDENSED_CONSOLIDATED_STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Parenthetical] (USD $)	Sep. 30, 2014
Acquisition of business, net cash acquired	$474

Description_of_Business_and_Ba

Description of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Business Description and Basis of Presentation [Text Block]	'
	1	Description of Business and Basis of Presentation
	Alliqua BioMedical, Inc. (the “Company”) is a provider of advanced wound care solutions. The Company’s primary business strategy is to create superior outcomes for patients, providers, and partners through its hydrogel technology platform and licensed and proprietary products.  The Company’s core businesses include advanced wound care and contract manufacturing. The Company seeks to leverage its proprietary hydrogel and licensed technology platform to add value to its own products and those of its partners.
	On May 5, 2014, the Company acquired Choice Therapeutics, Inc. (“Choice”), a privately held wound care company.
	On June 5, 2014, the Company’s shareholders approved an agreement and plan of merger between the Company and its wholly-owned Delaware subsidiary, Alliqua BioMedical, Inc., pursuant to which the Company merged with and into Alliqua BioMedical, Inc. for the sole purpose of changing the Company’s name to Alliqua BioMedical, Inc. and state of domicile from Florida to Delaware.
	Basis of Presentation
	The condensed consolidated financial statements contained in this report are unaudited. In the opinion of management, the condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the Company’s financial position as of September 30, 2014 and results of operations for the three and nine months ended September 30, 2014, and cash flows for the nine months ended September 30, 2014. While management believes that the disclosures presented are adequate to make the information not misleading, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto in the Company’s latest year-end financial statements, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 (the “2013 Annual Report”).  The results of the Company’s operations for any interim period are not necessarily indicative of the results of operations for any other interim period or for the full year.
	Principles of Consolidation
	The accompanying condensed consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries, AquaMed Technologies, Inc., HepaLife Biosystems, Inc. and Choice Therapeutics, Inc. All significant inter-company transactions and accounts have been eliminated in consolidation.
	Reclassifications
	Certain amounts in prior periods have been reclassified to conform to the current year presentation. Such reclassifications did not have a material effect on the Company’s financial condition or results of operations as previously reported.
	Significant Accounting Policies and Estimates
	The Company’s significant accounting policies are disclosed in Note 3 — Summary of Significant Accounting Policies in the 2013 Annual Report. Since the date of the 2013 Annual Report, there have been no material changes to the Company’s significant accounting policies. The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes.   These estimates and assumptions include valuing equity securities and derivative financial instruments issued in financing transactions, account receivable reserves, inventory reserves, deferred taxes and related valuation allowances, and the fair values of long lived assets, intangibles, goodwill and contingent consideration. Actual results could differ from the estimates.
	Recent Accounting Pronouncements
	In June 2014, the FASB issued Accounting Standards Update 2014-12, “Compensation — Stock Compensation: Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period” (“ASU 2014-12”).  ASU 2014-12 requires that a performance target that affects vesting of share-based payments and that could be achieved after the requisite service period be treated as a performance condition that affects vesting and as such, should not be reflected in estimating the grant-date fair value of the award.  ASU 2014-12 is effective for annual and interim periods beginning after December 15, 2015.  This standard is not expected to have a material effect on the Company’s financial position, results of operations or cash flows.

Net_Loss_Per_Common_Share

Net Loss Per Common Share	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	2. Net Loss Per Common Share
	Basic net loss per common share is computed based on the weighted average number of shares of common stock outstanding during the periods presented. Common stock equivalents, consisting of warrants, stock options, non-vested restricted stock units (“RSUs”), and non-vested shares of restricted stock were not included in the calculation of the diluted loss per share because their inclusion would have been anti-dilutive.
	The total common shares issuable upon the exercise of stock options, warrants, non-vested restricted stock units, and non-vested restricted stock are as follows:
		As of September 30,
		2014		2013
	Stock options		4,581,384		3,842,802
	Warrants		2,675,121		2,032,314
	Non-vested restricted stock units		-		70,753
	Non-vested restricted stock		234,323		-
	Total		7,490,828		5,945,869

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Business Combination Disclosure [Text Block]	'
	3	Acquisitions
	On May 5, 2014, the Company acquired all outstanding equity interest of Choice Therapeutics, Inc., a provider of innovative wound care products using proprietary Therabond 3D® Antimicrobial Barrier Systems.
	The Company’s initial cash payment for this acquisition was $2.0 million and approximately $2.0 million in stock. In addition to the initial cash payment, the Company may pay up to $5.0 million in contingent consideration which may be earned based upon the acquired company achieving specific performance metrics over the next three twelve month periods ended April 30, 2017. See Note 12 – Fair Value Measurement for details related to fair value of the contingent consideration.
	The assets and liabilities of the acquired business were included in the Company’s condensed consolidated balance sheet based upon estimated fair values on the date of acquisition as determined in a preliminary purchase price allocation, using available information and making assumptions management believes are reasonable. The Company is still in the process of completing its valuation of the assets, both tangible and intangible, and liabilities acquired. The condensed consolidated statements of operations include the results of the Choice operations beginning May 6, 2014. The Company’s preliminary allocation of purchase price for this acquisition is included in the table below, which summarizes the estimated fair value of the assets acquired and liabilities assumed at the date of acquisition:
	Consideration:
	Common stock		$	1,992,854
	Cash paid			2,000,000
	Fair value of contingent consideration			2,700,000
	Total consideration			6,692,854
	Cash and cash equivalents			474
	Inventory			396,961
	Other assets			11,587
	Tradenames			111,000
	Technology			2,396,000
	Customer relationships			176,000
	Goodwill			3,674,326
	Other liabilities			-73,494
	Net assets acquired		$	6,692,854
	The amortization period of intangible assets acquired ranges from 3 to 12 years. The Company recorded approximately $3.7 million of goodwill in connection with this acquisition, reflecting the strategic fit and revenue and earnings growth potential of this business.
	Revenues included in the condensed consolidated statement of operations for each of the three and nine month periods ended September 30, 2014 from this acquisition for the period subsequent to the closing of the transaction was approximately $577,000 and $900,000, respectively. Loss from operations included in the consolidated statement of operations for each of the three and nine month periods ended September 30, 2014 from this acquisition for the period subsequent to the closing of the transaction was approximately $162,000 and $179,000, respectively. Included in the loss from operations in each the three and nine month periods ended September 30, 2014 is approximately $194,000 relating to adjustments to the fair value of contingent consideration described below.
	The following unaudited pro forma results of operations for the three and nine months ended September 30, 2014 and 2013 assumes that the above acquisition was made at the beginning of the year prior to the acquisition. The pro forma results were calculated applying the Company’s accounting policies and reflect the elimination of transaction costs related to the acquisition that were included in the Company’s results of operations for the three and nine month periods ended September 30, 2014. The unaudited pro forma information does not purport to be indicative of the results that would have been obtained if the acquisitions had actually occurred at the beginning of the year prior to acquisition, nor of the results that may be reported in the future.
			Pro forma Results for the				Pro forma Results for the
			Three Months Ended September 30,				Nine Months Ended September 30,
			2014		2013		2014		2013
	Revenues		$	1,493,840	$	886,647	$	3,811,659	$	2,641,465
	Loss from operations		$	-4,902,351	$	-2,394,923	$	-20,201,822	$	-7,247,418
	During the three and nine month periods ended September 30, 2014, the Company incurred acquisition-related costs of approximately $61,000 and $546,000, respectively, in connection with due diligence, professional fees, and other expenses. Additionally, the Company adjusts the fair value of certain acquisition-related contingent consideration liabilities on a quarterly basis. For the three and nine month periods ended September 30, 2014, the adjustments resulted in a net increase of approximately $194,000 to the Company’s acquisition-related contingent consideration liability and corresponding increase in operating expenses.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
	4	Inventory
	Inventory consists of the following:
			September 30, 2014		December 31, 2013
	Raw materials		$	360,546	$	174,176
	Work in process			156,105		57,030
	Finished goods			593,492		346,843
	Less: Inventory reserve			-11,001		-76,580
	Total		$	1,099,142	$	501,469

Improvements_and_Equipment_net

Improvements and Equipment, net	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	5	Improvements and Equipment, net
	Improvements and equipment consist of the following:
			Useful Life	September 30, 2014		December 31, 2013
			(Years)
	Machinery and equipment		10	$	2,869,453	$	2,869,453
	Office furniture and equipment		10-Mar		51,440		44,844
	Leasehold improvements		(A)		228,021		228,021
					3,148,914		3,142,318
	Less: Accumulated depreciation and amortization				-1,636,351		-1,397,070
	Improvements and equipment, net			$	1,512,563	$	1,745,248
	(A) Leasehold improvements are amortized over the shorter of the remaining lease term or estimated useful life.
	Depreciation and amortization expense was $78,626 and $72,196 for the three months ended September 30, 2014 and 2013, respectively. Depreciation and amortization expense was $239,281 and $223,703 for the nine months ended September 30, 2014 and 2013, respectively.

Intangible_Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets Disclosure [Text Block]	'
	6	Intangible Assets
	The gross carrying amount and accumulated amortization of intangible assets are as follows:
				September 30, 2014
			Useful Life	Gross		Accumulated		Impairment		Net
			(Years)	Amount		Amortization				Carrying
										Amount
	Technology		10	$	5,396,000	$	-1,799,833	$	-	$	3,596,167
	Customer relationships		12		776,000		-291,482		-		484,518
	Distribution rights		5.27		400,000		-77,833		-		322,167
	Tradename		3		111,000		-15,417		-		95,583
	Non-compete		1		208,333		-86,805		-		121,528
				$	6,891,333	$	-2,271,370	$	-	$	4,619,963
				December 31, 2013
			Useful Life	Gross		Accumulated		Impairment		Net
			(Years)	Amount		Amortization				Carrying
										Amount
	In process research and development			$	8,100,000	$	-	$	-8,100,000	$	-
	Technology		10		3,000,000		-1,475,000		-		1,525,000
	Customer relationships		12		600,000		-245,834		-		354,166
	Distribution rights		5.27		400,000		-20,689		-		379,311
				$	12,100,000	$	-1,741,523	$	-8,100,000	$	2,258,477
	Amortization expense attributable to intangible assets for the three months ended September 30, 2014 and 2013 was $232,670 and $89,142, respectively. Amortization expense attributable to intangible assets for the nine months ended September 30, 2014 and 2013 was $529,847 and $264,142, respectively. During the year ended December 31, 2013, the Company recognized an impairment charge of $8,100,000 related to its in process research and development. Amortization expense for the years ending December 31, 2014, 2015, 2016, 2017, and 2018 is expected to be $232,670, $791,790, $722,346, $697,679, and $683,704, respectively.

Accrued_Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2014
Accrued Liabilities, Current [Abstract]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
		7	Accrued Expenses
	Accrued expenses consist of the following:
			September 30, 2014		December 31, 2013
	Salaries, benefits and incentive compensation		$	1,112,018	$	1,036,771
	Professional fees			224,906		83,317
	Royalty fees			314,588		-
	Inventory			-		127,786
	Other			137,487		20,025
	Total accrued expenses		$	1,788,999	$	1,267,899

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	8	Commitments and Contingencies
	Employment Agreements for Former Employees
	On March 14, 2014, a former executive of the Company resigned. Upon the executive’s resignation, the Company entered into a general release and severance agreement with this executive, pursuant to which, the employment agreement between the executive and the Company, dated September 28, 2012 was terminated, except for provisions relating to confidentiality and restrictive covenants. The Company provided the executive with: (i) payments totaling $385,000; (ii) the full and immediate vesting of all outstanding stock options and RSUs granted to this executive, with such stock options remaining exercisable for a period of two years following the date of resignation; and (iii) continued health insurance coverage during the six-month severance period. Of the total payments due to this executive, $210,000 was related to 2013 performance and included in accrued expenses as of December 31, 2013. The expense of the accelerated vesting of outstanding stock options and RSUs was $873,411 and is included in stock-based compensation for the nine months ended September 30, 2014.
	In March 2014, the Company entered into a general release and severance agreements with two employees, pursuant to which each employee’s employment with the Company was terminated effective immediately. The Company provided the employees with severance payments totaling $158,875 and accelerated vesting of one tranche of stock options granted to one of the employees, with such options remaining exercisable for a period of 90 days. The expense of the accelerated vesting of stock options was $24,171 and is included in stock-based compensation for the nine months ended September 30, 2014.
	Cooperative and License Agreements
	On July 15, 2011, the Company entered into a license agreement with Noble Fiber Technologies, LLC, whereby the Company has the exclusive right and license to manufacture and distribute “Silverseal Hydrogel Wound Dressings” and “Silverseal Hydrocolloid Wound Dressings”. The license is granted for ten years with an option to be extended for consecutive renewal periods of two years. An upfront license fee of $100,000 was expensed in 2011 as a selling, general and administrative expense. Royalties are to be paid equal to 9.75% of net sales of licensed products. The agreement calls for minimum royalties to be paid each calendar year as follows: 2013 - $200,000, 2014 - $400,000; 2015 - $500,000; and 2016 - $600,000. Total royalties charged to selling, general and administrative expense for the three months ended September 30, 2014 and 2013 were $100,000 and $50,000, respectively. Total royalties charged to selling, general and administrative expense for the nine months ended September 30, 2014 and 2013 were $300,000 and $150,000, respectively. $297,999 is included in accrued expenses as of September 30, 2014 in connection with this agreement.
	Sorbion Distributor Agreement
	On September 23, 2013, the Company entered into a distributor agreement (the “Sorbion Agreement”) with Sorbion GmbH & Co KG, pursuant to which the Company became the exclusive distributor of sorbion sachet S, sorbion sana and new products with hydrokinetic fibers as primary dressings in the United States, Canada and Latin America, subject to certain exceptions.
	The initial term of the agreement ends on December 31, 2018, and will be extended for additional one year terms until December 31, 2023, so long as the Company and Sorbion agree in September as to the minimum annual purchase amount for the calendar year that ends four years from the calendar year of such September.
	In order to maintain its exclusivity, the Company must purchase the following minimum amounts, in Euros, of the products for the indicated calendar year:
	Calendar Year		Minimum Annual Purchase Amount
	2014		500,000 Euros
	2015		1,000,000 Euros
	2016		2,500,000 Euros
	2017		4,000,000 Euros
	Since the Company must purchase the minimum amounts in Euros, the equivalent U.S. dollar expenditure will be subject to fluctuations in foreign currency exchange rates.
	The minimum annual purchase amounts in U.S. Dollars for each calendar year in the period from 2014-2017, based on the exchange rate as of September 30, 2014, are approximately $634,000, $1,269,000, $3,171,000, and $5,074,000, respectively.
	If the Company fails to purchase products in amounts that meet or exceed the minimum annual purchase amount for a calendar year, it may cure such minimum purchase failure by paying Sorbion in cash an amount equal to the minimum annual purchase amount for such calendar year less the amount the Company paid to Sorbion for the products purchased for such calendar year.  If the Company does not cure a minimum purchase failure with a makeup payment for a calendar year, Sorbion may terminate the Company’s exclusivity with respect to the products and grant the Company non-exclusive rights with respect to the products.  If the Company does not cure a minimum purchase failure for two subsequent calendar years, Sorbion may terminate the agreement.  The Company will not be required to meet the minimal annual purchase amount if Sorbion fails to supply the Company with the products in accordance with the agreement.  Sorbion may also terminate the Company’s exclusivity with respect to the products if the Company does not cure a material breach of the agreement within 30 days.
	Carolon Distribution Rights Agreement
	In September 2013, the Company entered into an agreement with Carolon Company (“Carolon”) pursuant to which, the Company purchased the distribution rights to the Sorbion sachet and sana products from Carolon. The Company is committed to pay Carolon (i) an aggregate payment of $400,000 in 12 equal monthly payments beginning November 2013, and (ii) if the Company sells at least $600,000 of certain Sorbion sachet products in the 2014 calendar year, $50,000 in January 2015.  This transaction was recorded as the purchase of distribution rights and was recorded as an intangible asset, subject to amortization over the remaining useful life of sixty-three months, and a corresponding liability of $400,000. In consideration of this agreement, an upfront fee of $50,000 for sales and training materials was expensed in the year ended December 31, 2013 as a selling, general and administrative expense. As of September 30, 2014, the balance of distribution rights payable was $33,333.
	Celgene License, Marketing and Development and Supply Agreement
	In November 2013, the Company entered into a License, Marketing and Development Agreement (the “License Agreement”) with Anthrogenesis Corporation, d/b/a Celgene Cellular Therapeutics (“CCT”), an affiliate of Celgene Corporation (“Celgene”), pursuant to which CCT granted the Company an exclusive, royalty-bearing license in its intellectual property for certain placental based products, including ECMs, an extracellularmatrix derived from the human placenta, and Biovance®, CCT’s proprietary wound coverings produced from decellularized, dehydrated humanamniotic membrane, to develop and commercialize ECMs and Biovance in the United States. Following the commencement of commercial sales of the licensed products, the Company will pay CCT annual license fees, designated amounts when certain milestone events occur and royalties on all sales of licensed products, with such amounts being variable and contingent on various factors. The initial term of the License Agreement ends on November 14, 2023, unless sooner terminated pursuant to the termination rights under the License Agreement, and will extend for additional two-year terms unless either party gives written notice within a specified period prior to the end of a term. The License Agreement may be terminated (i) by CCT if the Company or any of its affiliates challenges the validity, enforceability or scope of certain enumerated CCT patents anywhere in the world; (ii) by either party if there is a final decree that a licensed product infringed on the intellectual property of a third party; (iii) by either party for breach of the License Agreement, if the breach is not cured within a specified period after receiving written notice of the breach; or (iv) by either party if the other party is the subject of insolvency proceedings, either voluntary or involuntary. In addition, the License Agreement is terminable on a product-by-product basis, and not with respect to the entire License Agreement (i) by CCT in the second year of the License Agreement, and by either CCT or the Company in the third year of the License Agreement and beyond, if the Company fails to meet certain sales thresholds and (ii) by either party upon written notice if outside legal counsel recommends discontinuance of commercialization of a product because of significant safety, legal, or economic risk as a result of a claim, demand or action or as a result of a change in the interpretation of law by a governmental or regulatory authority. The License Agreement also contains mutual confidentiality and indemnification obligations for the Company and CCT. In September 2014, the Company entered into a First Amendment to the License Agreement (the “Amended License Agreement”), pursuant to which the Company received the right to market Biovance for podiatric and orthopedic applications. The Amended License Agreement also amends certain terms and the related schedule for milestone payments to CCT.
	In November 2013, the Company also entered into a Supply Agreement (the “Biovance Supply Agreement”) with CCT, pursuant to which CCT shall supply the Company with the Company’s entire requirements of Biovance for distribution and sale in the United States. The Biovance Supply Agreement will be terminated automatically upon the termination of the License Agreement and may otherwise be terminated (i) by CCT upon six months’ prior written notice, (ii) by the Company upon six months’ prior written notice if CCT fails to deliver at least a specified portion of a firm purchase order by the required delivery date specified in the order on at least a specified number of occasions in a specified period; (iii) by either party for breach of the Biovance Supply Agreement, if the breach is not cured within a specified period after receiving written notice of the breach; or (iv) by either party if the other party is the subject of insolvency proceedings, either voluntary or involuntary. On April 10, 2014, the Company and CCT entered into an amendment to the Biovance Supply Agreement in order to amend the pricing schedule.
	In April 2014, the Company entered into a Supply Agreement (the “ECM Supply Agreement”) with CCT, pursuant to which CCT shall, as soon as reasonably practicable after the date that CCT obtains regulatory clearance or approval in the United States for any of CCT’s extracellular matrix products derived from the human placenta (each an “ECM”), supply and sell to the Company all of the Company’s requirements of ECMs, in finished form and final packaging, for exploitation in the United States under the License Agreement. The ECM Supply Agreement will automatically terminate upon the termination or expiration of the License Agreement and may otherwise be terminated (i) by CCT upon six months’ prior written notice, (ii) by the Company upon six months’ prior written notice if CCT fails to deliver at least a specified portion of a firm purchase order by the required delivery date specified in the order on at least a specified number of occasions in a specified period; (iii) by either party for breach of the ECM Supply Agreement, if the breach is not cured within a specified period after receiving written notice of the breach; or (iv) by either party if the other party is the subject of insolvency proceedings, either voluntary or involuntary. The ECM Supply Agreement also contains mutual confidentiality and indemnification obligations for the Company and CCT.
	Litigation, Claims and Assessments
	The Company is subject to periodic lawsuits, investigations and claims that arise in the ordinary course of business.
	On February 27, 2014, ConvaTec Inc. filed suit against the Company and four of its current employees (each a former employee of ConvaTec Inc.), requesting injunctive relief for allegations involving breach of contract, tortious interference with employment agreements, unfair competition and common law conspiracy. ConvaTec Inc. is seeking, among other things, to enjoin the Company from continuing to employ a sales manager who is a former employee of ConvaTec, Inc. in a position related to wound care products and two sales representatives in positions related to wound care products in certain geographic areas.
	The Company fully disputes the allegations of ConvaTec Inc. and the relief sought to the fullest extent permitted by the law and believes them to be wholly without merit.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2014
Stockholders Equity Note [Abstract]	'
Stockholders Equity Note Disclosure [Text Block]	'
	9. Stockholders’ Equity
	Common Stock Issuances
	In April 2014, the Company entered into a securities purchase agreement pursuant to which the Company issued an aggregate of 2,139,287 shares of common stock, and five year warrants to purchase an aggregate of 427,858 shares of common stock at an exercise price of $10.50 per share, in exchange for aggregate consideration of approximately $14,975,000. The warrants become exercisable on October 15, 2014. In connection with the financing, the Company paid $598,500 in placement agent fees. Administrative fees for the escrow agent of $4,000 were also deducted from gross proceeds.
	2011 Plan
	The Company maintains the 2011 Long-Term Incentive Plan (the “2011 Plan”) that provides for the granting of stock options, RSUs, restricted stock and other awards to employees, directors and others. A total of 1,828,571 shares of common stock have been authorized for issuance under the 2011 Plan, of which, as of September 30, 2014, 21,300 shares were available for future issuances.
	2014 Plan
	On April 10, 2014 and June 5, 2014, the Company’s Board of Directors and the Company’s shareholders approved the 2014 Long-Term Incentive Plan (the “2014 Plan”), respectively. The 2014 Plan provides for the granting of stock options, RSUs, restricted stock and other awards to employees, directors and others. A total of 2,000,000 shares of common stock are reserved for award under the 2014 Plan, of which, as of September 30, 2014, 1,990,000 shares were available for future issuances.
	Stock-Based Compensation
	The following table summarizes stock-based compensation expense:
			Three Months Ended September 30,						Nine Months Ended September 30,
			2014			2013			2014			2013
	Options		$	1,450,527		$	473,200		$	6,361,366		$	2,271,842
	Warrants			13,496			7,447			208,530			7,447
	Restricted stock units			-			-34,395			180,715			-8,599
	Restricted stock			378,442			50,312			2,267,653			627,442
	Total stock-based compensation		$	1,842,465		$	496,564		$	9,018,264		$	2,898,132
	For the three months ended September 30, 2014, $63,331 of stock-based compensation is included in cost of revenues and $1,779,134 is included in selling, general and administrative expenses in the condensed consolidated statements of operations. For the nine months ended September 30, 2014, $143,184 of stock-based compensation is included in cost of revenues and $8,875,080 is included in selling, general and administrative expenses in the condensed consolidated statements of operations. For the three and nine months ended September 30, 2014, $496,564 and $2,898,132 of stock-based compensation is included in selling, general and administrative expense in the condensed consolidated statements of operations, respectively.
	Restricted Stock
	The following table summarizes the restricted stock issued as compensation during the nine months ended September 30, 2014:
	Issuance		Grantee		Shares			Vesting		Grant Date
	Date		Type		Issued			Term		Value
	1/6/14		Officer			369,395		[1]		$	2,582,072
	1/17/14		Consultant			1,107		Immediate			10,007
	1/27/14		Consultant			13,000		Immediate			118,300
	3/6/14		Employee			8,300		[2]			74,700
	3/9/14		Consultant			1,108		Immediate			10,005
	3/21/14		Consultant			1,136		Immediate			10,008
	4/2/14		Consultant			1,219		Immediate			10,008
	5/29/14		Consultant			1,000		Immediate			7,000
	6/16/14		Consultant			1,525		Immediate			10,004
	6/18/14		Consultant			1,558		Immediate			10,002
	7/1/14		Consultant			1,743		Immediate			10,005
			Restricted stock - total			401,091				$	2,852,111
		[1]	Vests in equal quarterly installments, with one-eighth vesting on January 6, 2014 and the remaining vesting on the first day of each calendar quarter thereafter.
		[2]	2,425 shares vest on each of March 6, 2014 and April 1, 2014. 1,725 shares vest on each of April 1, 2015 and April 1, 2016.
	On March 14, 2014, in connection with the resignation of the chief executive officer of a wholly-owned subsidiary of the Company, the Company accelerated the vesting of 17,688 RSUs that, prior to the modification, contained performance conditions which, for accounting purposes, were deemed improbable of being achieved. As a result, the Company recorded stock-based compensation expense of $157,069 during the nine months ended September 30, 2014, which represented the modification date value of the modified RSUs.
	As of September 30, 2014, there was $584,458 of unrecognized stock-based compensation expense related to restricted stock which will be amortized over a weighted average period of 0.7 years.
	A summary of common stock award activity during the nine months ended September 30, 2014 is presented below:
			Number of			Weighted			Total Grant
			Shares			Average			Date Fair
						Grant Date			Value
						Fair Value
	Non-vested, December 31, 2013			35,376		$	2.19		$	77,387
	Granted			401,091			7.11			2,852,111
	Vested			-202,144			6.36			-1,284,645
	Forfeited			-			-			-
	Non-vested, September 30, 2014			234,323		$	7.02		$	1,644,853
	Warrants
	See Note 9, Stockholders’ Equity – Common Stock Issuances for details related to new investor warrant issuances.
	There were no compensatory warrants issued during the nine months ended September 30, 2014.
	On April 11, 2014, the Company entered into a letter agreement with certain of the holders of warrants to purchase shares of the Company’s common stock that were granted pursuant to that certain securities purchase agreement, dated November 18, 2013, by and among the Company and the investors signatory thereto. The Company received approximately $5,293,000 from the exercising holders upon the exercise of the warrants, and the Company issued a total of 930,313 shares of common stock to the exercising holders pursuant to the terms of the warrants. In connection with the exercising holders exercising their warrants pursuant to the letter agreement, the Company paid $265,000 in placement agent fees and $2,500 of professional fees for the escrow agent, both of which were deducted from gross proceeds. The warrants, which were exercised at a price of $5.69 per share, had an aggregate intrinsic value of $1,544,320.
	During the nine months ended September 30, 2014, away from exercised warrants discussed above, the Company issued an aggregate of  258,295 shares of common stock to several holders of warrants who elected to exercise warrants to purchase an aggregate of  400,137 shares of common stock (353,137 shares on a "cashless" basis under the terms of the warrants and 47,000 shares for cash proceeds of $199,280). The warrants had exercise prices of $4.24 per share (241,060 gross shares), $3.02 per share (65,362 gross shares) and $2.19 per share (93,715 gross shares). The aggregate intrinsic value of the warrants exercised was $1,971,481 for the nine months ended September 30, 2014.
	As of September 30, 2014, there was $2,778 of unrecognized stock-based compensation expense related to compensatory warrants that are subject to non-employee mark-to-market adjustments and will be amortized over a weighted average period of  0.1 years.
	A summary of the warrant activity, including common stock purchase warrants, during the nine months ended September 30, 2014 is presented below:
			Number of			Weighted			Weighted			Intrinsic Value
			Warrants			Average			Average
						Exercise			Remaining
						Price			Life in
									Years
	Outstanding, December 31, 2013			3,822,557		$	5.12
	Issued			427,858			10.5
	Exercised			-1,330,450			5.03
	Cancelled			-244,844			7.88
Outstanding, September 30, 2014			2,675,121		$	5.76			3.9		$	992,672
Exercisable, September 30, 2014			2,236,694		$	4.86			3.8		$	989,362
The following table presents information related to warrants at September 30, 2014:
Warrants Outstanding						Warrants Exercisable
Exercise Price			Outstanding			Weighted			Exercisable
			Number of			Average			Number of
			Warrants			Remaining			Warrants
						Life in
						Years
$	2.19			108,572			3			108,572
	3.02			74,286			2.4			74,286
	3.5			2,286			2.6			2,286
	4.24			780,191			3.7			780,191
	4.38			188,444			4.1			181,401
	4.81			8,889			4.1			8,889
	5.69			1,040,880			4.1			1,037,354
	7			18,286			0.6			18,286
	8.75			25,429			0.8			25,429
	10.5			427,858			-			-
				2,675,121			3.8			2,236,694
As of September 30, 2014, five-year warrants to purchase an aggregate of 75,429 shares of common stock at an exercise price of $2.19 per share were deemed to be a derivative liability. See Note 12 – Fair Value Measurement.
Stock Options
During the nine months ended September 30, 2014, ten-year options to purchase an aggregate of 965,520 shares of common stock at exercise prices ranging from $5.09 to $9.05 with an aggregate grant date value of $5,991,640 were granted to directors and employees. Most of the grants vest over three years on the anniversaries of the grant date. Of the above, options to purchase 686,500 shares of common stock were granted pursuant to the 2011 Plan. The grant date value is being amortized over the vesting term.
In applying the Black-Scholes option pricing model to stock options granted, the Company used the following weighted average assumptions:
		Three Months Ended September 30,							Nine Months Ended September 30,
		2014				2013					2014		2013
Risk free interest rate			1.96	%			1.69	%			1.92	%		1.26	%
Expected term (years)			5.98				6.04				5.94			5.63
Expected volatility			100.56	%			99.87	%			102.36	%		99.17	%
Expected dividends			0	%			0	%			0	%		0	%
The risk-free interest rate is based on rates of treasury securities with the same expected term as the options. The Company uses the "simplified method" to calculate the expected term of employee and director stock-based options. The expected term used for consultants is the contractual life. The Company is utilizing an expected volatility figure based on a review of the Company’s historical volatility, over a period of time, equivalent to the expected life of the instrument being valued. The expected dividend yield is based upon the fact that the Company has not historically paid dividends, and does not expect to pay dividends in the near future.
The weighted average estimated fair value per share of the options granted during the three and nine months ended September 30, 2014 was $4.29 and $6.21, respectively. The weighted average estimated fair value per share of the options granted during the three and nine months ended September 30, 2013 was $2.27 and $2.07, respectively.
During the nine months ended September 30, 2014, the Company issued an aggregate of  277,150 shares of common stock to several holders of options who elected to exercise options to purchase an aggregate of  304,623 shares of common stock (57,143 shares on a "cashless" basis under the terms of the warrants and 247,480 shares for cash proceeds of $1,243,867). The options had exercise prices of $4.38 per share (222,964 gross shares), $5.47 per share (11,428 gross shares), $6.34 per share (22,857 gross shares) and $6.56 per share (47,374 gross shares). The aggregate intrinsic value of the options exercised was $920,201 for the nine months ended September 30, 2014.
As of September 30, 2014, there was $5,837,439 of unrecognized stock-based compensation expense related to stock options which will be amortized over a weighted average period of 1.7 years, of which $42,260 is subject to non-employee mark-to-market adjustments.
A summary of the stock option activity during the nine months ended September 30, 2014 is presented below:
		Number of			Weighted			Weighted			Intrinsic Value
		Options			Average			Average
					Exercise			Remaining
					Price			Life in
								Years
Outstanding, December 31, 2013			4,985,586		$	6.47
Granted			965,520			7.77
Exercised			-304,623			4.91
Forfeited			-1,065,099			7.2
Outstanding, September 30, 2014			4,581,384		$	6.68			8		$	1,035,407
Exercisable, September 30, 2014			2,185,063		$	5.41			6.9		$	1,014,931
The following table presents information related to stock options at September 30, 2014:
Options Outstanding						Options Exercisable
Exercise Price			Outstanding			Weighted			Exercisable
			Number of			Average			Number of
			Options			Remaining			Options
						Life in
						Years
$	3.28			279,227			8.4			279,227
	3.5			117,125			9.1			117,125
	3.94			7,619			9.1			7,619
	4.38			919,083			4.6			877,230
	5.09			10,000			-			-
	5.17			10,000			-			-
	5.29			14,000			9.8			776
	5.45			80,000			-			-
	5.47			97,713			8.6			65,142
	5.69			34,286			4.1			34,286
	5.91			27,142			6.3			17,142
	6.34			6,058			6.2			6,058
	6.56			445,064			8.4			197,484
	6.62			25,000			-			-
	6.79			10,000			-			-
	6.82			780,535			9.2			256,013
	6.83			10,000			-			-
	6.95			10,000			-			-
	6.99			241,520			9.3			35,380
	7.71			25,000			-			-
	7.9			10,000			-			-
	7.94			6,000			-			-
	8.5			25,000			9.4			6,250
	8.57			20,000			-			-
	8.75			732,565			8.3			236,571
	8.97			1,664			9.5			1,664
	8.99			30,000			-			-
	9			288,164			9.4			9,152
	9.04			20,000			-			-
	9.05			35,000			-			-
	10.94			262,245			8.6			36,570
	11.38			1,145			4			1,145
	26.69			229			3.7			229
				4,581,384			6.9			2,185,063

Related_Party

Related Party	9 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	10	Related Party
	On January 6, 2014, the Company entered into an option cancellation and release agreement with two former directors, pursuant to which each of the parties agreed to cancel options previously granted to purchase 278,096 shares of common stock of the Company at exercise prices ranging from $6.34 to $9.19.  In exchange for the cancellation of the options, the Company granted each individual 194,667 shares of common stock of the Company pursuant to 2011 Plan. The incremental expense for the exchange was $98,915 and is included in stock-based compensation for the nine months ended September 30, 2014.

Concentration_of_Risk

Concentration of Risk	9 Months Ended
	Sep. 30, 2014
Risks and Uncertainties [Abstract]	'
Concentration Risk Disclosure [Text Block]	'
	11	Concentration of Risk
	Revenues for the three months ended September 30, 2014 and 2013, and accounts receivable as of September 30, 2014 from our largest customers, both contract manufacturing customers, were as follows:
			% of Total Revenue					Accounts Receivable
	Customer		2014		2013			September 30, 2014
	A		22	%		43	%		24	%
	B		6	%		21	%		12	%
	Revenue for the nine months ended September 30, 2014 and 2013, were as follows:
				% of Total Revenue
	Customer			2014			2013
	A				31	%		51	%
	B				8	%		15	%

Fair_Value_Measurement

Fair Value Measurement	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	12	Fair Value Measurement
	Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are as follows:
	Level 1: Observable prices in active markets for identical assets and liabilities.
	Level 2: Observable inputs other than quoted prices in active markets for identical assets and liabilities.
	Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.
	During the nine months ended September 30, 2014, warrants to purchase an aggregate of  82,971 shares of common stock were exercised. These warrants had an aggregate exercise date fair value of $672,632 which was credited to equity. The Company recorded a loss on the change in fair value of these warrant of $202,393 during the nine months ended September 30, 2014. The Company recomputed the fair value of these warrant using the Binomial option pricing model (Level 3 inputs) using the following assumptions: expected volatility of  102.63%, risk-free rate of  1.19%-1.22%, expected term of  3.78-3.81 years, and expected dividends of  0.00%.
	On September 30, 2014, the Company recomputed the fair value of its remaining warrant liability as $280,157 using the Binomial option pricing model (Level 3 inputs) using the following assumptions: expected volatility of  100.56%, risk-free rate of  1.07%, expected term of  3.11 years, and expected dividends of  0.00%. The Company recorded a gain on the change in fair value of these warrant liabilities of $183,069 during the nine months ended September 30, 2014.
	The following table sets forth a summary of the changes in the fair value of Level 3 warrant liabilities that are measured at fair value on a recurring basis:
	Warrant Liabilities
	Beginning balance as of January 1, 2014		$	933,465
	Change in fair value of warrant liability			19,324
	Value of warrants exercised			-672,632
	Ending balance as of September 30, 2014		$	280,157
	Contingent Consideration
	Beginning balance as of January 1, 2014		$	-
	Fair value of contingent consideration			2,700,000
	Change in fair value of contingent consideration			194,034
	Ending balance as of September 30, 2014		$	2,894,034
	Assets and liabilities measured at fair value on a recurring or nonrecurring basis are as follows:
			September 30, 2014
			Level 1		Level 2		Level 3
	Liabilities:
	Warrant liabilities		$	-	$	-	$	280,157
	Contingent consideration		$	-	$	-	$	2,894,034
	Total liabilities		$	-	$	-	$	3,174,191
			December 31, 2013
			Level 1		Level 2		Level 3
	Liabilities:
	Warrant liabilities		$	-	$	-	$	933,465
	Total liabilities		$	-	$	-	$	933,465
	Warrants that contain exercise reset provisions and contingent consideration liabilities are Level 3 derivative liabilities measured at fair value on a recurring basis using pricing models for which at least one significant assumption is unobservable as defined in ASC 820. The fair value of contingent consideration liabilities that was classified as Level 3 in the table above was estimated using a discounted cash flow technique with significant inputs that are not observable in the market and thus represents a Level 3 fair value measurement as defined in ASC 820. The significant inputs in the Level 3 measurement not supported by market activity include the probability assessments of expected future cash flows related to the acquisitions, appropriately discounted considering the uncertainties associated with the obligation, and as calculated in accordance with the terms of the acquisition agreements. The development and determination of the unobservable inputs for Level 3 fair value measurements and the fair value calculations are the responsibility of the Company’s chief financial officer and are approved by the chief executive officer.

Description_of_Business_and_Ba1

Description of Business and Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	Basis of Presentation
	The condensed consolidated financial statements contained in this report are unaudited. In the opinion of management, the condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the Company’s financial position as of September 30, 2014 and results of operations for the three and nine months ended September 30, 2014, and cash flows for the nine months ended September 30, 2014. While management believes that the disclosures presented are adequate to make the information not misleading, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto in the Company’s latest year-end financial statements, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 (the “2013 Annual Report”).  The results of the Company’s operations for any interim period are not necessarily indicative of the results of operations for any other interim period or for the full year.
Consolidation, Policy [Policy Text Block]	'
	Principles of Consolidation
	The accompanying condensed consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries, AquaMed Technologies, Inc., HepaLife Biosystems, Inc. and Choice Therapeutics, Inc. All significant inter-company transactions and accounts have been eliminated in consolidation.
Reclassification, Policy [Policy Text Block]	'
	Reclassifications
	Certain amounts in prior periods have been reclassified to conform to the current year presentation. Such reclassifications did not have a material effect on the Company’s financial condition or results of operations as previously reported.
Significant Accounting Policies and Estimates [Policy Text Block]	'
	Significant Accounting Policies and Estimates
	The Company’s significant accounting policies are disclosed in Note 3 — Summary of Significant Accounting Policies in the 2013 Annual Report. Since the date of the 2013 Annual Report, there have been no material changes to the Company’s significant accounting policies. The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes.   These estimates and assumptions include valuing equity securities and derivative financial instruments issued in financing transactions, account receivable reserves, inventory reserves, deferred taxes and related valuation allowances, and the fair values of long lived assets, intangibles, goodwill and contingent consideration. Actual results could differ from the estimates.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recent Accounting Pronouncements
	In June 2014, the FASB issued Accounting Standards Update 2014-12, “Compensation — Stock Compensation: Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period” (“ASU 2014-12”).  ASU 2014-12 requires that a performance target that affects vesting of share-based payments and that could be achieved after the requisite service period be treated as a performance condition that affects vesting and as such, should not be reflected in estimating the grant-date fair value of the award.  ASU 2014-12 is effective for annual and interim periods beginning after December 15, 2015.  This standard is not expected to have a material effect on the Company’s financial position, results of operations or cash flows.

Net_Loss_Per_Common_Share_Tabl

Net Loss Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
	The total common shares issuable upon the exercise of stock options, warrants, non-vested restricted stock units, and non-vested restricted stock are as follows:
		As of September 30,
		2014		2013
	Stock options		4,581,384		3,842,802
	Warrants		2,675,121		2,032,314
	Non-vested restricted stock units		-		70,753
	Non-vested restricted stock		234,323		-
	Total		7,490,828		5,945,869

Acquisitions_Tables

Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	'
	The Company’s preliminary allocation of purchase price for this acquisition is included in the table below, which summarizes the estimated fair value of the assets acquired and liabilities assumed at the date of acquisition:
	Consideration:
	Common stock	$	1,992,854
	Cash paid		2,000,000
	Fair value of contingent consideration		2,700,000
	Total consideration		6,692,854
	Cash and cash equivalents		474
	Inventory		396,961
	Other assets		11,587
	Tradenames		111,000
	Technology		2,396,000
	Customer relationships		176,000
	Goodwill		3,674,326
	Other liabilities		-73,494
	Net assets acquired	$	6,692,854
Business Acquisition, Pro Forma Information [Table Text Block]	'
	The unaudited pro forma information does not purport to be indicative of the results that would have been obtained if the acquisitions had actually occurred at the beginning of the year prior to acquisition, nor of the results that may be reported in the future.
		Pro forma Results for the				Pro forma Results for the
		Three Months Ended September 30,				Nine Months Ended September 30,
		2014		2013		2014		2013
	Revenues	$	1,493,840	$	886,647	$	3,811,659	$	2,641,465
	Loss from operations	$	-4,902,351	$	-2,394,923	$	-20,201,822	$	-7,247,418

Inventory_Tables

Inventory (Tables)	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
	Inventory consists of the following:
		September 30, 2014		December 31, 2013
	Raw materials	$	360,546	$	174,176
	Work in process		156,105		57,030
	Finished goods		593,492		346,843
	Less: Inventory reserve		-11,001		-76,580
	Total	$	1,099,142	$	501,469

Improvements_and_Equipment_net1

Improvements and Equipment, net (Tables)	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Improvements and equipment consist of the following:
		Useful Life	September 30, 2014		December 31, 2013
		(Years)
	Machinery and equipment	10	$	2,869,453	$	2,869,453
	Office furniture and equipment	10-Mar		51,440		44,844
	Leasehold improvements	(A)		228,021		228,021
				3,148,914		3,142,318
	Less: Accumulated depreciation and amortization			-1,636,351		-1,397,070
	Improvements and equipment, net		$	1,512,563	$	1,745,248
	(A) Leasehold improvements are amortized over the shorter of the remaining lease term or estimated useful life.

Intangible_Assets_Tables

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2014
Finite-Lived Intangible Assets, Net [Abstract]	'
Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]	'
	The gross carrying amount and accumulated amortization of intangible assets are as follows:
			September 30, 2014
		Useful Life	Gross		Accumulated		Impairment		Net
		(Years)	Amount		Amortization				Carrying
									Amount
	Technology	10	$	5,396,000	$	-1,799,833	$	-	$	3,596,167
	Customer relationships	12		776,000		-291,482		-		484,518
	Distribution rights	5.27		400,000		-77,833		-		322,167
	Tradename	3		111,000		-15,417		-		95,583
	Non-compete	1		208,333		-86,805		-		121,528
			$	6,891,333	$	-2,271,370	$	-	$	4,619,963
			December 31, 2013
		Useful Life	Gross		Accumulated		Impairment		Net
		(Years)	Amount		Amortization				Carrying
									Amount
	In process research and development		$	8,100,000	$	-	$	-8,100,000	$	-
	Technology	10		3,000,000		-1,475,000		-		1,525,000
	Customer relationships	12		600,000		-245,834		-		354,166
	Distribution rights	5.27		400,000		-20,689		-		379,311
			$	12,100,000	$	-1,741,523	$	-8,100,000	$	2,258,477

Accrued_Expenses_Tables

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2014
Accrued Liabilities, Current [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
	Accrued expenses consist of the following:
		September 30, 2014		December 31, 2013
	Salaries, benefits and incentive compensation	$	1,112,018	$	1,036,771
	Professional fees		224,906		83,317
	Royalty fees		314,588		-
	Inventory		-		127,786
	Other		137,487		20,025
	Total accrued expenses	$	1,788,999	$	1,267,899

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Long-term Purchase Commitment [Table Text Block]	'
	In order to maintain its exclusivity, the Company must purchase the following minimum amounts, in Euros, of the products for the indicated calendar year:
	Calendar Year	Minimum Annual Purchase Amount
	2014	500,000 Euros
	2015	1,000,000 Euros
	2016	2,500,000 Euros
	2017	4,000,000 Euros

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2014
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
	The following table summarizes stock-based compensation expense:
			Three Months Ended September 30,						Nine Months Ended September 30,
			2014			2013			2014			2013
	Options		$	1,450,527		$	473,200		$	6,361,366		$	2,271,842
	Warrants			13,496			7,447			208,530			7,447
	Restricted stock units			-			-34,395			180,715			-8,599
	Restricted stock			378,442			50,312			2,267,653			627,442
	Total stock-based compensation		$	1,842,465		$	496,564		$	9,018,264		$	2,898,132
Nonvested Restricted Stock Shares Activity [Table Text Block]	'
	The following table summarizes the restricted stock issued as compensation during the nine months ended September 30, 2014:
	Issuance		Grantee		Shares			Vesting		Grant Date
	Date		Type		Issued			Term		Value
	1/6/14		Officer			369,395		[1]		$	2,582,072
	1/17/14		Consultant			1,107		Immediate			10,007
	1/27/14		Consultant			13,000		Immediate			118,300
	3/6/14		Employee			8,300		[2]			74,700
	3/9/14		Consultant			1,108		Immediate			10,005
	3/21/14		Consultant			1,136		Immediate			10,008
	4/2/14		Consultant			1,219		Immediate			10,008
	5/29/14		Consultant			1,000		Immediate			7,000
	6/16/14		Consultant			1,525		Immediate			10,004
	6/18/14		Consultant			1,558		Immediate			10,002
	7/1/14		Consultant			1,743		Immediate			10,005
			Restricted stock - total			401,091				$	2,852,111
		[1]	Vests in equal quarterly installments, with one-eighth vesting on January 6, 2014 and the remaining vesting on the first day of each calendar quarter thereafter.
		[2]	2,425 shares vest on each of March 6, 2014 and April 1, 2014. 1,725 shares vest on each of April 1, 2015 and April 1, 2016.
Schedule of Nonvested Share Activity [Table Text Block]	'
	A summary of common stock award activity during the nine months ended September 30, 2014 is presented below:
			Number of			Weighted			Total Grant
			Shares			Average			Date Fair
						Grant Date			Value
						Fair Value
	Non-vested, December 31, 2013			35,376		$	2.19		$	77,387
	Granted			401,091			7.11			2,852,111
	Vested			-202,144			6.36			-1,284,645
	Forfeited			-			-			-
	Non-vested, September 30, 2014			234,323		$	7.02		$	1,644,853
Employee Stock Option [Member]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	A summary of the stock option activity during the nine months ended September 30, 2014 is presented below:
			Number of			Weighted			Weighted			Intrinsic Value
			Options			Average			Average
						Exercise			Remaining
						Price			Life in
									Years
	Outstanding, December 31, 2013			4,985,586		$	6.47
	Granted			965,520			7.77
	Exercised			-304,623			4.91
	Forfeited			-1,065,099			7.2
	Outstanding, September 30, 2014			4,581,384		$	6.68			8		$	1,035,407
	Exercisable, September 30, 2014			2,185,063		$	5.41			6.9		$	1,014,931
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	'
	The following table presents information related to stock options at September 30, 2014:
	Options Outstanding						Options Exercisable
	Exercise Price			Outstanding			Weighted			Exercisable
				Number of			Average			Number of
				Options			Remaining			Options
							Life in
							Years
	$	3.28			279,227			8.4			279,227
		3.5			117,125			9.1			117,125
		3.94			7,619			9.1			7,619
		4.38			919,083			4.6			877,230
		5.09			10,000			-			-
		5.17			10,000			-			-
		5.29			14,000			9.8			776
		5.45			80,000			-			-
		5.47			97,713			8.6			65,142
		5.69			34,286			4.1			34,286
		5.91			27,142			6.3			17,142
		6.34			6,058			6.2			6,058
		6.56			445,064			8.4			197,484
		6.62			25,000			-			-
		6.79			10,000			-			-
		6.82			780,535			9.2			256,013
		6.83			10,000			-			-
		6.95			10,000			-			-
		6.99			241,520			9.3			35,380
		7.71			25,000			-			-
		7.9			10,000			-			-
		7.94			6,000			-			-
		8.5			25,000			9.4			6,250
		8.57			20,000			-			-
		8.75			732,565			8.3			236,571
		8.97			1,664			9.5			1,664
		8.99			30,000			-			-
		9			288,164			9.4			9,152
		9.04			20,000			-			-
		9.05			35,000			-			-
		10.94			262,245			8.6			36,570
		11.38			1,145			4			1,145
		26.69			229			3.7			229
					4,581,384			6.9			2,185,063
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following weighted average assumptions:
			Three Months Ended September 30,							Nine Months Ended September 30,
			2014				2013					2014		2013
	Risk free interest rate			1.96	%			1.69	%			1.92	%		1.26	%
	Expected term (years)			5.98				6.04				5.94			5.63
	Expected volatility			100.56	%			99.87	%			102.36	%		99.17	%
	Expected dividends			0	%			0	%			0	%		0	%
Warrant [Member]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	A summary of the warrant activity, including common stock purchase warrants, during the nine months ended September 30, 2014 is presented below:
			Number of			Weighted			Weighted			Intrinsic Value
			Warrants			Average			Average
						Exercise			Remaining
						Price			Life in
									Years
	Outstanding, December 31, 2013			3,822,557		$	5.12
	Issued			427,858			10.5
	Exercised			-1,330,450			5.03
	Cancelled			-244,844			7.88
	Outstanding, September 30, 2014			2,675,121		$	5.76			3.9		$	992,672
	Exercisable, September 30, 2014			2,236,694		$	4.86			3.8		$	989,362
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	'
	The following table presents information related to warrants at September 30, 2014:
	Warrants Outstanding						Warrants Exercisable
	Exercise Price			Outstanding			Weighted			Exercisable
				Number of			Average			Number of
				Warrants			Remaining			Warrants
							Life in
							Years
	$	2.19			108,572			3			108,572
		3.02			74,286			2.4			74,286
		3.5			2,286			2.6			2,286
		4.24			780,191			3.7			780,191
		4.38			188,444			4.1			181,401
		4.81			8,889			4.1			8,889
		5.69			1,040,880			4.1			1,037,354
		7			18,286			0.6			18,286
		8.75			25,429			0.8			25,429
		10.5			427,858			-			-
					2,675,121			3.8			2,236,694

Concentration_of_Risk_Tables

Concentration of Risk (Tables)	9 Months Ended
	Sep. 30, 2014
Risks and Uncertainties [Abstract]	'
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	'
	Revenues for the three months ended September 30, 2014 and 2013, and accounts receivable as of September 30, 2014 from our largest customers, both contract manufacturing customers, were as follows:
		% of Total Revenue					Accounts Receivable
	Customer	2014		2013			September 30, 2014
	A	22	%		43	%		24	%
	B	6	%		21	%		12	%
	Revenue for the nine months ended September 30, 2014 and 2013, were as follows:
			% of Total Revenue
	Customer		2014			2013
	A			31	%		51	%
	B			8	%		15	%

Fair_Value_Measurement_Tables

Fair Value Measurement (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
	The following table sets forth a summary of the changes in the fair value of Level 3 warrant liabilities that are measured at fair value on a recurring basis:
	Warrant Liabilities
	Beginning balance as of January 1, 2014	$	933,465
	Change in fair value of warrant liability		19,324
	Value of warrants exercised		-672,632
	Ending balance as of September 30, 2014	$	280,157
	Contingent Consideration
	Beginning balance as of January 1, 2014	$	-
	Fair value of contingent consideration		2,700,000
	Change in fair value of contingent consideration		194,034
	Ending balance as of September 30, 2014	$	2,894,034
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	'
	Assets and liabilities measured at fair value on a recurring or nonrecurring basis are as follows:
		September 30, 2014
		Level 1		Level 2		Level 3
	Liabilities:
	Warrant liabilities	$	-	$	-	$	280,157
	Contingent consideration	$	-	$	-	$	2,894,034
	Total liabilities	$	-	$	-	$	3,174,191
		December 31, 2013
		Level 1		Level 2		Level 3
	Liabilities:
	Warrant liabilities	$	-	$	-	$	933,465
	Total liabilities	$	-	$	-	$	933,465

Net_Loss_Per_Common_Share_Deta

Net Loss Per Common Share (Details)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	7,490,828	5,945,869
Stock Option [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4,581,384	3,842,802
Warrant [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,675,121	2,032,314
Non-vested Restricted Stock Units [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	70,753
Non-vested Restricted Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	234,323	0

Acquisitions_Details

Acquisitions (Details) (USD $)	9 Months Ended			0 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	5-May-14	5-May-14	5-May-14	5-May-14
				Choice Therapeutics, Inc. [Member]	Choice Therapeutics, Inc. [Member]	Choice Therapeutics, Inc. [Member]	Choice Therapeutics, Inc. [Member]
					Trade Names [Member]	Technology-Based Intangible Assets [Member]	Customer Relationships [Member]
Consideration:	'	'	'	'	'	'	'
Common stock	'	'	'	$1,992,854	'	'	'
Cash paid	'	'	'	2,000,000	'	'	'
Fair value of contingent consideration	2,700,000	0	'	2,700,000	'	'	'
Total consideration	'	'	'	6,692,854	'	'	'
Cash and cash equivalents	474	'	'	474	'	'	'
Inventory	'	'	'	396,961	'	'	'
Other assets	'	'	'	11,587	'	'	'
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	'	'	'	'	111,000	2,396,000	176,000
Goodwill	4,100,295	'	425,969	3,674,326	'	'	'
Other liabilities	'	'	'	-73,494	'	'	'
Net assets acquired	'	'	'	$6,692,854	'	'	'

Acquisitions_Details_1

Acquisitions (Details 1) (Choice Therapeutics, Inc. [Member], USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Choice Therapeutics, Inc. [Member]	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'
Revenues	$1,493,840	$886,647	$3,811,659	$2,641,465
Loss from operations	($4,902,351)	($2,394,923)	($20,201,822)	($7,247,418)

Acquisitions_Details_Textual

Acquisitions (Details Textual) (USD $)	3 Months Ended		9 Months Ended		3 Months Ended	9 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2014	5-May-14	Sep. 30, 2014	Sep. 30, 2014
					Choice Therapeutics, Inc. [Member]	Choice Therapeutics, Inc. [Member]	Choice Therapeutics, Inc. [Member]	Choice Therapeutics, Inc. [Member]	Choice Therapeutics, Inc. [Member]
								Minimum [Member]	Maximum [Member]
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'	'
Business Combination, Contingent Consideration, Liability	'	'	'	'	'	'	$5,000,000	'	'
Finite-Lived Intangible Asset, Useful Life	'	'	'	'	'	'	'	'3 years	'12 years
Revenues, Total	1,493,840	437,985	3,121,863	1,328,911	577,000	900,000	'	'	'
Operating Income (Loss)	-5,157,715	-2,265,762	-20,086,381	-6,773,516	162,000	179,000	'	'	'
Business Combination, Acquisition Related Costs	61,330	0	546,970	0	61,000	546,000	'	'	'
Business Combination Contingent Consideration Adjustments to Fair Value	'	'	'	'	$194,000	$194,000	'	'	'

Inventory_Details

Inventory (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Inventory [Line Items]	'	'
Raw materials	$360,546	$174,176
Work in process	156,105	57,030
Finished goods	593,492	346,843
Less: Inventory reserve	-11,001	-76,580
Total	$1,099,142	$501,469

Improvements_and_Equipment_net2

Improvements and Equipment, net (Details) (USD $)	Sep. 30, 2014		Dec. 31, 2013		Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
					Machinery and Equipment [Member]	Office Equipment [Member]	Office Equipment [Member]	Leasehold Improvements [Member]
						Maximum [Member]	Minimum [Member]
Property, Plant and Equipment [Line Items]	'		'		'	'	'	'
Machinery and equipment	$2,869,453		$2,869,453		'	'	'	'
Office furniture and equipment	51,440		44,844		'	'	'	'
Leasehold improvements	228,021	[1]	228,021	[1]	'	'	'	'
Property, Plant and Equipment, Gross, Total	3,148,914		3,142,318		'	'	'	'
Less: Accumulated depreciation and amortization	-1,636,351		-1,397,070		'	'	'	'
Improvements and equipment, net	$1,512,563		$1,745,248		'	'	'	'
Property, Plant and Equipment, Useful Life	'		'		'10 years	'10 years	'3 years	'	[1]
[1]	Leasehold improvements are amortized over the shorter of the remaining lease term or estimated useful life.

Improvements_and_Equipment_net3

Improvements and Equipment, net (Details Textual) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Property, Plant and Equipment [Line Items]	'	'	'	'
Depreciation, Depletion and Amortization, Total	$78,626	$72,196	$239,281	$223,703

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Amount	$6,891,333	$12,100,000
Accumulated Amortization	-2,271,370	-1,741,523
Impairment	0	-8,100,000
Net Carrying Amount	4,619,963	2,258,477
In process research and development [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Amount	'	8,100,000
Accumulated Amortization	'	0
Impairment	'	-8,100,000
Net Carrying Amount	'	0
Technology [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful Life	'10 years	'10 years
Gross Amount	5,396,000	3,000,000
Accumulated Amortization	-1,799,833	-1,475,000
Impairment	0	0
Net Carrying Amount	3,596,167	1,525,000
Customer relationships [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful Life	'12 years	'12 years
Gross Amount	776,000	600,000
Accumulated Amortization	-291,482	-245,834
Impairment	0	0
Net Carrying Amount	484,518	354,166
Distribution rights [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful Life	'5 years 3 months 7 days	'5 years 3 months 7 days
Gross Amount	400,000	400,000
Accumulated Amortization	-77,833	-20,689
Impairment	0	0
Net Carrying Amount	322,167	379,311
Trade Names [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful Life	'3 years	'
Gross Amount	111,000	'
Accumulated Amortization	-15,417	'
Impairment	0	'
Net Carrying Amount	95,583	'
Noncompete Agreements [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful Life	'1 year	'
Gross Amount	208,333	'
Accumulated Amortization	-86,805	'
Impairment	0	'
Net Carrying Amount	$121,528	'

Intangible_Assets_Details_Text

Intangible Assets (Details Textual) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Finite-Lived Intangible Assets [Line Items]	'	'	'	'
Amortization of Intangible Assets	$232,670	$89,142	$529,847	$264,142
Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year	232,670	'	232,670	'
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	791,790	'	791,790	'
Finite-Lived Intangible Assets, Amortization Expense, Year Two	722,346	'	722,346	'
Finite-Lived Intangible Assets, Amortization Expense, Year Three	697,679	'	697,679	'
Finite-Lived Intangible Assets, Amortization Expense, Year Four	$683,704	'	$683,704	'

Accrued_Expenses_Details

Accrued Expenses (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Accrued Liabilities Current Line Items [Line Items]	'	'
Salaries, benefits and incentive compensation	$1,112,018	$1,036,771
Professional fees	224,906	83,317
Royalty fees	314,588	0
Inventory	0	127,786
Other	137,487	20,025
Total accrued expenses	$1,788,999	$1,267,899

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (EUR €)	Sep. 30, 2014
Commitments And Contingencies [Line Items]	'
2014	€ 500,000
2015	1,000,000
2016	2,500,000
2017	€ 4,000,000

Commitments_and_Contingencies_2

Commitments and Contingencies (Details Textual) (USD $)

3 Months Ended

9 Months Ended

9 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2011

Jan. 31, 2015

Sep. 30, 2014

Sep. 30, 2014

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Sorbion Sachet [Member]

Alliqua Biomedical Subsidiary [Member]

Alliqua Biomedical Subsidiary [Member]

Alliqua Biomedical Subsidiary [Member]

Alliqua Biomedical Subsidiary [Member]

Alliqua Biomedical Subsidiary [Member]

Carolon Company [Member]

Carolon Company [Member]

Carolon Company [Member]

Noble Fiber Technologies License Agreement [Member]

Subsequent Event [Member]

Executive Employment Agreement Two [Member]

Sorbion Distributor Agreement [Member]

Sorbion Sachet [Member]

Commitments And Contingencies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Upfront License Fees

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$100,000

'

'

'

Royalty Fee Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9.75%

'

'

'

Contractual Obligation, Future Minimum Payments Due, Remainder of Fiscal Year

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

'

'

'

'

'

Contractual Obligation, Due in Next Twelve Months

'

'

'

'

'

'

'

'

'

'

'

'

400,000

'

'

'

'

'

'

'

Contractual Obligation, Due in Second Year

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

Contractual Obligation, Due in Third Year

'

'

'

'

'

'

'

'

'

'

'

'

600,000

'

'

'

'

'

'

'

Royalty Expense

'

'

'

'

'

'

'

'

100,000

50,000

300,000

150,000

'

'

'

'

'

'

'

'

Contractual Obligation, Total

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

400,000

'

'

'

'

Minimum Sales Commitment

'

'

'

'

'

'

'

600,000

'

'

'

'

'

'

'

'

'

50,000

'

'

Upfront Fee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

'

'

'

'

'

Distribution Rights Payable

33,333

'

33,333

'

333,333

'

'

'

'

'

'

'

'

33,333

'

'

'

'

'

'

Finite-Lived Intangible Assets, Remaining Amortization Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'63 months

'

'

'

'

'

'

Allocated Share-based Compensation Expense

1,779,134

496,564

8,875,080

2,898,132

'

873,411

'

'

'

'

'

'

'

'

'

'

'

'

24,171

'

Co-operative and License Agreements, License Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

Co-operative and License Agreements, License Renewal Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2 years

'

'

'

Recorded Unconditional Purchase Obligation, Due in Remainder of Fiscal Year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

634,000

Recorded Unconditional Purchase Obligation, Due in Next Rolling Twelve Months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,269,000

Recorded Unconditional Purchase Obligation, Due in Rolling Year Two

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,171,000

Recorded Unconditional Purchase Obligation, Due in Rolling Year Three

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,074,000

Accrued Liabilities, Current

$1,788,999

'

$1,788,999

'

$1,267,899

$385,000

$210,000

'

$297,999

'

$297,999

'

'

'

'

'

'

'

$158,875

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term

'

'

'

'

'

'2 years

'

'

'

'

'

'

'

'

'

'

'

'

'90 days

'

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Total stock-based compensation	$1,779,134	$496,564	$8,875,080	$2,898,132
Share Based Compensation Plan [Member] | Restricted stock units [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Total stock-based compensation	0	-34,395	180,715	-8,599
Share Based Compensation Plan [Member] | Restricted stock [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Total stock-based compensation	378,442	50,312	2,267,653	627,442
Share Based Compensation Plan [Member] | Warrants [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Total stock-based compensation	13,496	7,447	208,530	7,447
Share Based Compensation Plan [Member] | Options [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Total stock-based compensation	$1,450,527	$473,200	$6,361,366	$2,271,842

Stockholders_Equity_Details_1

Stockholders' Equity (Details 1) (Restricted Stock [Member], USD $)	9 Months Ended
	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Shares Isued	401,091
Grant Date Value	$2,852,111
Officer [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Issuance Date	6-Jan-14
Shares Isued	369,395
Vesting Term	'[1]	[1]
Grant Date Value	2,582,072
Consultant One [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Issuance Date	17-Jan-14
Shares Isued	1,107
Vesting Term	'Immediate
Grant Date Value	10,007
Consultant Two [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Issuance Date	27-Jan-14
Shares Isued	13,000
Vesting Term	'Immediate
Grant Date Value	118,300
Employee [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Issuance Date	6-Mar-14
Shares Isued	8,300
Vesting Term	'[2]	[2]
Grant Date Value	74,700
Consultant Three [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Issuance Date	9-Mar-14
Shares Isued	1,108
Vesting Term	'Immediate
Grant Date Value	10,005
Consultant Four [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Issuance Date	21-Mar-14
Shares Isued	1,136
Vesting Term	'Immediate
Grant Date Value	10,008
Consultant Five [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Issuance Date	2-Apr-14
Shares Isued	1,219
Vesting Term	'Immediate
Grant Date Value	10,008
Consultant Six [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Issuance Date	29-May-14
Shares Isued	1,000
Vesting Term	'Immediate
Grant Date Value	7,000
Consultant Seven [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Issuance Date	16-Jun-14
Shares Isued	1,525
Vesting Term	'Immediate
Grant Date Value	10,004
Consultant Eight [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Issuance Date	18-Jun-14
Shares Isued	1,558
Vesting Term	'Immediate
Grant Date Value	10,002
Consultant Nine [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Issuance Date	1-Jul-14
Shares Isued	1,743
Vesting Term	'Immediate
Grant Date Value	$10,005
[1]	Vests in equal quarterly installments, with one-eighth vesting on January 6, 2014 and the remaining vesting on the first day of each calendar quarter thereafter.
[2]	2,425 shares vest on each of March 6, 2014 and April 1, 2014. 1,725 shares vest on each of April 1, 2015 and April 1, 2016.

Stockholders_Equity_Details_2

Stockholders' Equity (Details 2) (Restricted Stock [Member], USD $)	9 Months Ended
	Sep. 30, 2014
Restricted Stock [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number of Shares, Non-vested, December 31, 2013 (in shares)	35,376
Number of Shares, Granted (in shares)	401,091
Number of Shares, Vested (in shares)	-202,144
Number of Shares, Forfeited (in shares)	0
Number of Shares, Non-vested, September 30, 2014 (in shares)	234,323
Weighted Average Grant Date Fair Value, Non-vested, December 31, 2013 (in dollars per share)	$2.19
Weighted Average Grant Date Fair Value, Granted (in dollars per share)	$7.11
Weighted Average Grant Date Fair Value, Vested (in dollars per share)	$6.36
Weighted Average Grant Date Fair Value, Forfeited (in dollars per share)	$0
Weighted Average Grant Date Fair Value, Non-vested, September 30, 2014 (in dollars per share)	$7.02
Total Grant Date Fair Value, Non-vested, December 31, 2013	$77,387
Total Grant Date Fair Value, Granted	2,852,111
Total Grant Date Fair Value, Vested	-1,284,645
Total Grant Date Fair Value, Forfeited	0
Total Grant Date Fair Value, Non-vested, September 30, 2014	$1,644,853

Stockholders_Equity_Details_3

Stockholders' Equity (Details 3) (Warrant [Member], USD $)	9 Months Ended
	Sep. 30, 2014
Warrant [Member]	'
Statement [Line Items]	'
Number Of Warrants Outstanding, December 31 2013 (in shares)	3,822,557
Number of Warrants, Issued	427,858
Number of Warrants, Exercised	-1,330,450
Number of Warrants, Cancelled	-244,844
Number Of Warrants Outstanding, September 30, 2014 (in shares)	2,675,121
Number of Warrants, Exercisable, September 30, 2014 (in shares)	2,236,694
Weighted Average Exercise Price, Outstanding, December 31 2013, (in dollars per share)	$5.12
Weighted Average Exercise Price, Issued (in dollars per share)	$10.50
Weighted Average Exercise Price, Exercised (in dollars per share)	$5.03
Weighted Average Exercise Price, Cancelled (in dollars per share)	$7.88
Weighted Average Exercise Price, Outstanding, September 30, 2014 (in dollars per share)	$5.76
Weighted Average Exercise Price, Exercisable September 30, 2014 (in dollars per share)	$4.86
Weighted Average Remaining Life In Years, Outstanding, September 30, 2014 (Years)	'3 years 10 months 24 days
Weighted Average Remaining Life In Years, Exercisable, Exercisable, September 30, 2014 (Years)	'3 years 9 months 18 days
Intrinsic Value, Outstanding, September 30, 2014	$992,672
Intrinsic Value, Exercisable, September 30, 2014	$989,362

Stockholders_Equity_Details_4

Stockholders' Equity (Details 4) (Warrant [Member], USD $)	9 Months Ended
	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Outstanding, Number of Warrants	2,675,121
Warrants Exercisable, Weighted Average Remaining Life In Years	'3 years 9 months 18 days
Warrants Exercisable, Number of Warrants	2,236,694
Exercise Price Range, 2.19 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Outstanding, Exercise Price	2.19
Warrants Outstanding, Number of Warrants	108,572
Warrants Exercisable, Weighted Average Remaining Life In Years	'3 years
Warrants Exercisable, Number of Warrants	108,572
Exercise Price Range, 3.02 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Outstanding, Exercise Price	3.02
Warrants Outstanding, Number of Warrants	74,286
Warrants Exercisable, Weighted Average Remaining Life In Years	'2 years 4 months 24 days
Warrants Exercisable, Number of Warrants	74,286
Exercise Price Range, 3.50 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Outstanding, Exercise Price	3.5
Warrants Outstanding, Number of Warrants	2,286
Warrants Exercisable, Weighted Average Remaining Life In Years	'2 years 7 months 6 days
Warrants Exercisable, Number of Warrants	2,286
Exercise Price Range, 4.24 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Outstanding, Exercise Price	4.24
Warrants Outstanding, Number of Warrants	780,191
Warrants Exercisable, Weighted Average Remaining Life In Years	'3 years 8 months 12 days
Warrants Exercisable, Number of Warrants	780,191
Exercise Price Range, 4.38 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Outstanding, Exercise Price	4.38
Warrants Outstanding, Number of Warrants	188,444
Warrants Exercisable, Weighted Average Remaining Life In Years	'4 years 1 month 6 days
Warrants Exercisable, Number of Warrants	181,401
Exercise Price Range, 4.81 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Outstanding, Exercise Price	4.81
Warrants Outstanding, Number of Warrants	8,889
Warrants Exercisable, Weighted Average Remaining Life In Years	'4 years 1 month 6 days
Warrants Exercisable, Number of Warrants	8,889
Exercise Price Range, 5.69 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Outstanding, Exercise Price	5.69
Warrants Outstanding, Number of Warrants	1,040,880
Warrants Exercisable, Weighted Average Remaining Life In Years	'4 years 1 month 6 days
Warrants Exercisable, Number of Warrants	1,037,354
Exercise Price Range, 7.00 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Outstanding, Exercise Price	7
Warrants Outstanding, Number of Warrants	18,286
Warrants Exercisable, Weighted Average Remaining Life In Years	'7 months 6 days
Warrants Exercisable, Number of Warrants	18,286
Exercise Price Range, 8.75 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Outstanding, Exercise Price	8.75
Warrants Outstanding, Number of Warrants	25,429
Warrants Exercisable, Weighted Average Remaining Life In Years	'9 months 18 days
Warrants Exercisable, Number of Warrants	25,429
Exercise Price Range, 10.50 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Outstanding, Exercise Price	10.5
Warrants Outstanding, Number of Warrants	427,858
Warrants Exercisable, Weighted Average Remaining Life In Years	'0 years
Warrants Exercisable, Number of Warrants	0

Stockholders_Equity_Details_5

Stockholders' Equity (Details 5) (Stock Options [Member])	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Stock Options [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Risk free interest rate	1.96%	1.69%	1.92%	1.26%
Expected term (years)	'5 years 11 months 23 days	'6 years 14 days	'5 years 11 months 8 days	'5 years 7 months 17 days
Expected volatility	100.56%	99.87%	102.36%	99.17%
Expected dividends	0.00%	0.00%	0.00%	0.00%

Stockholders_Equity_Details_6

Stockholders' Equity (Details 6) (Stock Options [Member], USD $)	9 Months Ended
	Sep. 30, 2014
Stock Options [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number Of Warrants Outstanding, December 31 2013 (in shares)	4,985,586
Number of Options, Granted (in shares)	965,520
Number of Options, Exercised (in shares)	-304,623
Number of Options, Forfeited (in shares)	-1,065,099
Number Of Warrants Outstanding, September 30, 2014 (in shares)	4,581,384
Number of Options, Exercisable, September 30, 2014 (in shares)	2,185,063
Weighted Average Exercise Price, Outstanding, December 31 2013, (in dollars per share)	$6.47
Weighted Average Exercise Price, Granted (in dollars per share)	$7.77
Weighted Average Exercise Price, Exercised (in dollars per share)	$4.91
Weighted Average Exercise Price, Forfeited (in dollars per share)	$7.20
Weighted Average Exercise Price, Outstanding, September 30, 2014 (in dollars per share)	$6.68
Weighted Average Exercise Price, Exercisable September 30, 2014 (in dollars per share)	$5.41
Weighted Average Remaining Life In Years, Outstanding, September 30, 2014 (Years)	'8 years
Weighted Average Remaining Life In Years, Exercisable, Exercisable, September 30, 2014 (Years)	'6 years 10 months 24 days
Intrinsic Value, Outstanding, September 30, 2014	$1,035,407
Intrinsic Value, Exercisable, September 30, 2014	$1,014,931

Stockholders_Equity_Details_7

Stockholders' Equity (Details 7) (Stock Options [Member], USD $)	9 Months Ended
	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Outstanding Number of Options (in shares)	4,581,384
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'6 years 10 months 24 days
Options Exercisable, Exercisable Number of Options (in shares)	2,185,063
Exercise Price Range 3.28 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	3.28
Options Outstanding, Outstanding Number of Options (in shares)	279,227
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'8 years 4 months 24 days
Options Exercisable, Exercisable Number of Options (in shares)	279,227
Exercise Price Range 3.5 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	3.5
Options Outstanding, Outstanding Number of Options (in shares)	117,125
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'9 years 1 month 6 days
Options Exercisable, Exercisable Number of Options (in shares)	117,125
Exercise Price Range 3.94 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	3.94
Options Outstanding, Outstanding Number of Options (in shares)	7,619
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'9 years 1 month 6 days
Options Exercisable, Exercisable Number of Options (in shares)	7,619
Exercise Price Range, 4.38 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	4.38
Options Outstanding, Outstanding Number of Options (in shares)	919,083
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'4 years 7 months 6 days
Options Exercisable, Exercisable Number of Options (in shares)	877,230
Exercise Price Range 5.09 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	5.09
Options Outstanding, Outstanding Number of Options (in shares)	10,000
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'0 years
Options Exercisable, Exercisable Number of Options (in shares)	0
Exercise Price Range 5.17 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	5.17
Options Outstanding, Outstanding Number of Options (in shares)	10,000
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'0 years
Options Exercisable, Exercisable Number of Options (in shares)	0
Exercise Price Range 5.29 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	5.29
Options Outstanding, Outstanding Number of Options (in shares)	14,000
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'9 years 9 months 18 days
Options Exercisable, Exercisable Number of Options (in shares)	776
Exercise Price Range 5.45 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	5.45
Options Outstanding, Outstanding Number of Options (in shares)	80,000
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'0 years
Options Exercisable, Exercisable Number of Options (in shares)	0
Exercise Price Range 5.47 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	5.47
Options Outstanding, Outstanding Number of Options (in shares)	97,713
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'8 years 7 months 6 days
Options Exercisable, Exercisable Number of Options (in shares)	65,142
Exercise Price Range, 5.69 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	5.69
Options Outstanding, Outstanding Number of Options (in shares)	34,286
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'4 years 1 month 6 days
Options Exercisable, Exercisable Number of Options (in shares)	34,286
Exercise Price Range 5.91 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	5.91
Options Outstanding, Outstanding Number of Options (in shares)	27,142
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'6 years 3 months 18 days
Options Exercisable, Exercisable Number of Options (in shares)	17,142
Exercise Price Range 6.34 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	6.34
Options Outstanding, Outstanding Number of Options (in shares)	6,058
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'6 years 2 months 12 days
Options Exercisable, Exercisable Number of Options (in shares)	6,058
Exercise Price Range 6.56 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	6.56
Options Outstanding, Outstanding Number of Options (in shares)	445,064
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'8 years 4 months 24 days
Options Exercisable, Exercisable Number of Options (in shares)	197,484
Exercise Price Range 6.62 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	6.62
Options Outstanding, Outstanding Number of Options (in shares)	25,000
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'0 years
Options Exercisable, Exercisable Number of Options (in shares)	0
Exercise Price Range 6.79 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	6.79
Options Outstanding, Outstanding Number of Options (in shares)	10,000
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'0 years
Options Exercisable, Exercisable Number of Options (in shares)	0
Exercise Price Range 6.82 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	6.82
Options Outstanding, Outstanding Number of Options (in shares)	780,535
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'9 years 2 months 12 days
Options Exercisable, Exercisable Number of Options (in shares)	256,013
Exercise Price Range 6.83 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	6.83
Options Outstanding, Outstanding Number of Options (in shares)	10,000
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'0 years
Options Exercisable, Exercisable Number of Options (in shares)	0
Exercise Price Range 6.95 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	6.95
Options Outstanding, Outstanding Number of Options (in shares)	10,000
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'0 years
Options Exercisable, Exercisable Number of Options (in shares)	0
Exercise Price Range 6.99 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	6.99
Options Outstanding, Outstanding Number of Options (in shares)	241,520
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'9 years 3 months 18 days
Options Exercisable, Exercisable Number of Options (in shares)	35,380
Exercise Price Range 7.71 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	7.71
Options Outstanding, Outstanding Number of Options (in shares)	25,000
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'0 years
Options Exercisable, Exercisable Number of Options (in shares)	0
Exercise Price Range 7.90 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	7.9
Options Outstanding, Outstanding Number of Options (in shares)	10,000
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'0 years
Options Exercisable, Exercisable Number of Options (in shares)	0
Exercise Price Range 7.94 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	7.94
Options Outstanding, Outstanding Number of Options (in shares)	6,000
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'0 years
Options Exercisable, Exercisable Number of Options (in shares)	0
Exercise Price Range 8.5 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	8.5
Options Outstanding, Outstanding Number of Options (in shares)	25,000
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'9 years 4 months 24 days
Options Exercisable, Exercisable Number of Options (in shares)	6,250
Exercise Price Range 8.57 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	8.57
Options Outstanding, Outstanding Number of Options (in shares)	20,000
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'0 years
Options Exercisable, Exercisable Number of Options (in shares)	0
Exercise Price Range, 8.75 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	8.75
Options Outstanding, Outstanding Number of Options (in shares)	732,565
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'8 years 3 months 18 days
Options Exercisable, Exercisable Number of Options (in shares)	236,571
Exercise Price Range 8.97 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	8.97
Options Outstanding, Outstanding Number of Options (in shares)	1,664
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'9 years 6 months
Options Exercisable, Exercisable Number of Options (in shares)	1,664
Exercise Price Range 8.99 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	8.99
Options Outstanding, Outstanding Number of Options (in shares)	30,000
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'0 years
Options Exercisable, Exercisable Number of Options (in shares)	0
Exercise Price Range 9 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	9
Options Outstanding, Outstanding Number of Options (in shares)	288,164
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'9 years 4 months 24 days
Options Exercisable, Exercisable Number of Options (in shares)	9,152
Exercise Price Range 9.04 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	9.04
Options Outstanding, Outstanding Number of Options (in shares)	20,000
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'0 years
Options Exercisable, Exercisable Number of Options (in shares)	0
Exercise Price Range 9.05 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	9.05
Options Outstanding, Outstanding Number of Options (in shares)	35,000
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'0 years
Options Exercisable, Exercisable Number of Options (in shares)	0
Exercise Price Range 10.94 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	10.94
Options Outstanding, Outstanding Number of Options (in shares)	262,245
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'8 years 7 months 6 days
Options Exercisable, Exercisable Number of Options (in shares)	36,570
Exercise Price Range 11.38 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	11.38
Options Outstanding, Outstanding Number of Options (in shares)	1,145
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'4 years
Options Exercisable, Exercisable Number of Options (in shares)	1,145
Exercise Price Range 26.69 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price (in dollars per share)	26.69
Options Outstanding, Outstanding Number of Options (in shares)	229
Options Exercisable, Weighted Average Remaining Life in Years (in years)	'3 years 8 months 12 days
Options Exercisable, Exercisable Number of Options (in shares)	229

Stockholders_Equity_Details_Te

Stockholders' Equity (Details Textual) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Apr. 30, 2014

Sep. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Plan 2011 [Member]

Plan 2011 [Member]

Plan 2014 [Member]

Minimum [Member]

Maximum [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

4.38 Exercise Price [Member]

5.47 Exercise Price [Member]

6.34 Exercise Price [Member]

6.56 Exercise Price [Member]

5.69 Warrant [Member]

CEO of Subsidiary [Member]

Employee [Member]

Employee [Member]

Employee [Member]

Employee [Member]

Non Employee Director [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Cashless Excisable [Member]

Excisable in Cash [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Placement Agent Fees [Member]

Administrative Fees [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Vesting Date March 6, 2014 [Member]

Vesting Date April 1, 2014 [Member]

Vesting Date April 1, 2015 [Member]

Vesting Date April 1, 2016 [Member]

Employee Stock Option [Member]

Employee [Member]

Cashless Excisable [Member]

Excisable in Cash [Member]

Placement Agent Fees [Member]

Administrative Fees [Member]

3.02 Exercise Price [Member]

4.24 Exercise Price [Member]

2.19 Exercise Price [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total

'

'

'

'

$5,837,439

'

$5,837,439

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$42,260

$584,458

'

$2,778

'

'

'

'

'

'

'

Warrants To Purchase Common Stock

'

'

82,971

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

75,429

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

17,688

'

'

'

'

'

202,144

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

'

'

'

'

'

'

'1 year 8 months 12 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'8 months 12 days

'

'1 month 6 days

'

'

'

'

'

'

'

Stock Issued During Period Shares Warrants Exercised

'

'

'

'

'

'

277,150

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

258,295

'

'

'

'

'

'

'

Number Of Warrants To Purchase Common Stock Exercised

'

'

'

'

'

'

304,623

'

57,143

247,480

'

'

'

'

'

'

'

'

'

427,858

'

'

'

222,964

11,428

22,857

47,374

1,544,320

'

'

'

'

'

'

'

'

400,137

353,137

47,000

'

'

65,362

241,060

93,715

Warrants Exercised, Intrinsic Value

'

'

'

'

'

'

920,201

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,971,481

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,828,571

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Capital Shares Reserved for Future Issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Allocated Share-based Compensation Expense

1,779,134

496,564

8,875,080

2,898,132

'

'

'

'

'

'

63,331

143,184

1,779,134

8,875,080

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,425

2,425

1,725

1,725

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation, Total

'

'

8,822,925

2,270,690

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

157,069

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

'

'

'

'

'

'

686,500

'

'

'

'

'

'

'

21,300

965,520

1,990,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

401,091

8,300

427,858

'

'

'

'

'

'

'

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5.09

$9.05

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$10.50

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value

'

'

'

'

'

'

5,991,640

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,852,111

74,700

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

'

'

'

'

$4.29

$2.27

$6.21

$2.07

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$7.11

'

'

'

'

'

'

'

'

'

Investment Warrants, Exercise Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$10.50

'

'

'

$4.38

$5.47

$6.34

$6.56

$5.69

'

'

'

'

'

'

'

'

$2.19

'

'

'

'

$3.02

$4.24

$2.19

Stock Issued During Period, Shares, New Issues

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,139,287

2,139,287

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

930,313

'

'

'

'

'

'

'

Proceeds from Issuance of Common Stock

'

'

14,372,503

3,291,293

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14,975,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments of Stock Issuance Costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

602,500

598,500

4,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

265,000

2,500

'

'

'

Proceeds from Warrant Exercises

'

'

$5,225,587

$0

'

'

'

'

'

$1,243,867

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5,293,000

'

$199,280

'

'

'

'

'

Related_Party_Details_Textual

Related Party (Details Textual) (USD $)	9 Months Ended
	Sep. 30, 2014
Option Cancellation and Release Agreement [Member]	'
Related Party Transaction [Line Items]	'
Stock Granted, Value, Share-based Compensation, Forfeited	$278,096
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	$98,915
Option Cancellation and Release Agreement [Member] | Director One [Member]	'
Related Party Transaction [Line Items]	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total	194,667
Option Cancellation and Release Agreement [Member] | Director Two [Member]	'
Related Party Transaction [Line Items]	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total	194,667
Option Cancellation and Release Agreement [Member] | Minimum [Member]	'
Related Party Transaction [Line Items]	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$6.34
Option Cancellation and Release Agreement [Member] | Maximum [Member]	'
Related Party Transaction [Line Items]	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$9.19
Common Stock [Member]	'
Related Party Transaction [Line Items]	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total	836,491	[1]
[1]	Includes $307,189 that was part of accrued expenses as of December 31, 2013 and for the the year then ended, which was credited to equity upon the issuance of 34,086 restricted common shares during the nine months ended September 30, 2014.

Concentration_of_Risk_Details

Concentration of Risk (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Sales Revenue, Net [Member] | Customer A [Member]	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration Risk, Percentage	22.00%	43.00%	31.00%	51.00%
Sales Revenue, Net [Member] | Customer B [Member]	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration Risk, Percentage	6.00%	21.00%	8.00%	15.00%
Accounts Receivable [Member] | Customer A [Member]	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration Risk, Percentage	24.00%	'	'	'
Accounts Receivable [Member] | Customer B [Member]	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration Risk, Percentage	12.00%	'	'	'

Fair_Value_Measurement_Details

Fair Value Measurement (Details) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Beginning balance as of January 1, 2014	$0	'
Fair value of contingent consideration	2,700,000	0
Ending balance as of September 30, 2014	2,894,034	'
Warrant Liabilities [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Beginning balance as of January 1, 2014	933,465	'
Change in fair value	19,324	'
Value of warrants exercised	-672,632	'
Ending balance as of September 30, 2014	280,157	'
Contingent Consideration [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Beginning balance as of January 1, 2014	0	'
Fair value of contingent consideration	2,700,000	'
Change in fair value	194,034	'
Ending balance as of September 30, 2014	$2,894,034	'

Fair_Value_Measurement_Details1

Fair Value Measurement (Details 1) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Fair Value, Inputs, Level 1 [Member]	'	'
Liabilities:	'	'
Warrant liabilities	$0	$0
Contingent consideration	0	'
Total liabilities	0	0
Fair Value, Inputs, Level 2 [Member]	'	'
Liabilities:	'	'
Warrant liabilities	0	0
Contingent consideration	0	'
Total liabilities	0	0
Fair Value, Inputs, Level 3 [Member]	'	'
Liabilities:	'	'
Warrant liabilities	280,157	933,465
Contingent consideration	2,894,034	'
Total liabilities	$3,174,191	$933,465

Fair_Value_Measurement_Details2

Fair Value Measurement (Details Textual) (USD $)	0 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Warrants To Purchase Common Stock	'	82,971
Fair Value, Liabilities Measured on Recurring Basis, Change in Unrealized Gain (Loss)	$183,069	($202,393)
Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair Value Assumptions, Expected Volatility Rate	100.56%	102.63%
Fair Value Assumptions, Risk Free Interest Rate	1.07%	'
Fair Value Assumptions, Expected Term	'3 years 1 month 10 days	'
Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%
Fair Value, Inputs, Level 3 [Member] | Maximum [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair Value Assumptions, Risk Free Interest Rate	'	1.19%
Fair Value Assumptions, Expected Term	'	'3 years 9 months 22 days
Fair Value, Inputs, Level 3 [Member] | Minimum [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair Value Assumptions, Risk Free Interest Rate	'	1.22%
Fair Value Assumptions, Expected Term	'	'3 years 9 months 11 days